Femasys receives second order from spain partners after successfully completing commercial femaseed® infertility treatments

Atlanta, oct. 02, 2024 (globe newswire) -- femasys, inc., (nasdaq: femy), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the company has received its second order from its strategic distribution partners after successfully completing its first commercial femaseed® procedures in europe. members of the femasys team traveled to madrid to in-service healthcare practitioners on the innovative femaseed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.
FEMY Ratings Summary
FEMY Quant Ranking